Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expect

Event · Earnings
Original reporting
Published Nov 16, 2026, 2:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ELOX
Bearish
high confidence
Mentioned
$ELOX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ELOXBearishMed
01

Why it matters

Earnings miss and cash burn are likely to pressure the stock, but trial initiation may provide a near‑term catalyst.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; modest trading relevance focused on trial progress and cash position.

03

What to watch

Potential Breakthrough Therapy designation discussions with FDA could materially improve valuation if data are positive.

Relevance 7/10Novelty 7/10Timing: today
AlphAI · Earnings readELOX · Q3 2026 · ended 2026-09-30

Eloxx starts Phase 2b EXACT study and clears EXPRESS IND; net loss widens to $(5,543) thousand in Q3 2026 with no revenue reported

→Mixed quarter

The release reports clinical progress: first two patients dosed in the Phase 2b EXACT study, IND clearance for the EXPRESS study, and a new Chief Medical Officer. Against that, the net loss and operating expenses rose sharply year over year, no revenue line is reported, and cash fell from $62.0 million at June 30, 2026 to $56.3 million at September 30, 2026. The company states cash is sufficient to fund operations into 2028.

EPS · GAAP
$(0.49)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, Q3 2026GAAP$4.03M––
General and administrative expenses, Q3 2026GAAP$1.93M––
Total operating expenses, Q3 2026GAAP$5.95M––
Loss from operations, Q3 2026GAAP−$5.95M––
Other income, net, Q3 2026GAAP$400K––
Net loss, Q3 2026GAAP−$5.54M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.49)––
Research and development expenses, nine months 2026GAAP$8.53M––
General and administrative expenses, nine months 2026GAAP$5.67M––
Total operating expenses, nine months 2026GAAP$14.20M––
Loss from operations, nine months 2026GAAP−$14.20M––
Other income (expense), net, nine months 2026GAAP$400 thousand income (presented as (400) thousand in the statement of operations)––
Net loss, nine months 2026GAAP−$13.80M––
Net loss per share, basic and diluted, nine months 2026GAAP$(1.83)––
Cash and cash equivalents, September 30, 2026GAAP$56.3 million ($56,264 thousand)––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The company effected a one-for-eleven reverse stock split of its common stock in May 2026. All share and per-share amounts in the release reflect the split.
  • The authorized shares of common stock were reduced from 500,000,000 to 100,000,000 in connection with the reverse split.
  • The release refers to a June 2026 public offering that increased cash balances. The offering size and proceeds are not stated in the document.

What drove it

  • Company explanation for R&D: the increase to $4.0 million was primarily related to higher clinical trial expenses associated with the initiation of the Phase 2b EXACT study, as well as increases in personnel costs.
  • The company states that Q3 2025 R&D was reduced by a $0.9 million write-off of accounts payable balances with certain vendors under settlement agreements.
  • Company explanation for G&A: the increase to $1.9 million was primarily related to higher professional and consulting fees, including legal, audit and tax fees, increased personnel costs, and higher facility and other overhead costs.
  • Company explanation for other income, net: the change to $0.4 million of income was primarily related to higher interest income on increased cash balances following the June 2026 public offering and lower interest expense.
  • Pipeline progress: first two patients dosed in the Phase 2b EXACT study (NCT07523581) in nonsense mutation Alport syndrome in September 2026.
  • Pipeline progress: FDA clearance of the IND for exaluren in nmADPKD announced October 29, 2026, enabling U.S. clinical sites for the Phase 2 EXPRESS study.
  • Leadership: T.R. Srinivas, M.D., appointed Senior Vice President and Chief Medical Officer in October 2026. Geno Germano appointed to the Board effective October 19, 2026.

Concerns

  • Net loss for Q3 2026 was $(5,543) thousand, compared with $(351) thousand in Q3 2025. Net loss for nine months 2026 was $(13,799) thousand, compared with $(3,951) thousand.
  • Total operating expenses for Q3 2026 were $5,953 thousand, compared with $285 thousand in Q3 2025, and nine-month operating expenses were $14,199 thousand, compared with $3,089 thousand.
  • Cash and cash equivalents declined from $62.0 million at June 30, 2026 to $56.3 million at September 30, 2026.
  • The company states its cash is sufficient to fund operations into 2028, which is shorter than the 52-week EXPRESS data timing of the first half of 2029 and the EXPRESS first patient timing of the third quarter of 2027. The filing does not state whether additional capital will be needed.
  • The forward-looking statements section lists the company's need for and ability to obtain additional capital as a risk factor.
  • Per-share figures reflect the one-for-eleven reverse stock split, so per-share loss comparisons across periods are affected by the split as stated in the release.

What to watch

  • Topline data from the 16-week placebo-controlled portion of the Phase 2b EXACT study, expected in mid-2027.
  • Final 32-week data from the EXACT study, expected by the end of 2027.
  • First patient dosed in the Phase 2 EXPRESS study in nmADPKD, expected in the third quarter of 2027.
  • 52-week topline data from EXPRESS, expected in the first half of 2029.
  • Whether FDA grants Breakthrough Therapy Designation for exaluren in nmADPKD. The release states any designation would depend on clinical results and further FDA review.
  • Cash runway and any future financing, given the company's statement that cash funds operations into 2028.
  • Operating expense trend as the EXACT and EXPRESS studies progress, given the Q3 2026 increase in R&D and G&A.

Balance sheet and cash flow

  • Cash and cash equivalents: $56,264 thousand at September 30, 2026, compared with $4,785 thousand at December 31, 2025, and $62.0 million at June 30, 2026 as stated in the text.
  • Total assets: $58,261 thousand at September 30, 2026, compared with $5,270 thousand at December 31, 2025.
  • Total current liabilities: $17,192 thousand at September 30, 2026, compared with $17,177 thousand at December 31, 2025.
  • Total stockholders' equity (deficit): $41,069 thousand at September 30, 2026, compared with $(11,907) thousand at December 31, 2025.
  • The company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.
  • No operating cash flow, investing cash flow, financing cash flow or debt figures are reported in the document.

Analysis

Eloxx reported a clinical-stage third quarter with no revenue line in the document. Total operating expenses rose to $5,953 thousand in Q3 2026 from $285 thousand in Q3 2025, and the net loss widened to $(5,543) thousand from $(351) thousand. The company attributes the R&D increase mainly to clinical trial expenses for the initiation of the Phase 2b EXACT study and to higher personnel costs, and the G&A increase mainly to professional and consulting fees, personnel costs and facility and overhead costs. The Q3 2025 R&D figure was a net credit of $(250) thousand, which the company says was reduced by a $0.9 million vendor settlement write-off, so the year-over-year R&D comparison is distorted by that prior-period item.

For nine months 2026, R&D was $8,528 thousand against $1,158 thousand, and G&A was $5,671 thousand against $1,931 thousand. Net loss for nine months was $(13,799) thousand, or $(1.83) per share, against $(3,951) thousand, or $(9.12) per share. The release states that all per-share amounts reflect the one-for-eleven reverse stock split effected in May 2026, and the weighted average share counts in the statement of operations differ sharply between the periods, so per-share figures should be read with that split in mind.

Other income, net was $0.4 million in Q3 2026 against other expense, net of $0.1 million in Q3 2025. The company attributes the change to higher interest income on cash balances following the June 2026 public offering and lower interest expense. The offering size is not stated in the document.

On the balance sheet, cash and cash equivalents were $56.3 million at September 30, 2026, down from $62.0 million at June 30, 2026 and up from $4,785 thousand at December 31, 2025. Stockholders' equity moved to $41,069 thousand from a deficit of $(11,907) thousand at year-end 2025. The company states cash is sufficient to fund operations into 2028. No operating or financing cash flow figures are printed, so the quarterly cash decline cannot be traced to its components from this document.

Operationally, the quarter's milestones were the first two patients dosed in the Phase 2b EXACT study, FDA IND clearance for exaluren in nmADPKD announced October 29, 2026, the finalized 52-week EXPRESS design targeting about 60 adults, and the appointment of a Chief Medical Officer. No guidance was provided in the release, so no outlook comparison is possible.

Management, verbatim

The third quarter marked important progress for Eloxx, as we dosed the first two patients in our Phase 2b EXACT study in nonsense mutation Alport syndrome. With the EXPRESS protocol finalized and IND clearance in hand, we now have two programs in rare kidney disease,

Sumit Aggarwal, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Revenue and collaboration income: the document reports no revenue line. The company describes a licensing arrangement with Almirall for ZKN-013 but does not print any revenue or milestone figure for it.
  • Prior-quarter (Q2 2026) operating expense, net loss and EPS figures: not printed in the document, so sequential comparisons are null.
  • Year-over-year and sequential percentage changes for all metrics: not printed.
  • Cash and cash equivalents at September 30, 2025: not printed. The December 31, 2025 figure is given but is not the same-period prior-year comparison.
  • Operating cash flow, investing cash flow, financing cash flow and free cash flow: not printed.
  • Size and gross proceeds of the June 2026 public offering: not printed.
  • Financial guidance or outlook for 2026 or later financial results: not provided.
  • Total debt and any borrowings: not printed.
  • Consensus estimates and share price reaction: not provided and not included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

The filing is an SEC Form 8‑K reporting Eloxx's quarterly financials and clinical updates for its exaluren program.

Company-level read

Ticker impact

$ELOXBearishHigh confidence
Context

Eloxx Pharmaceuticals filed its 3Q 2026 results, reporting a $5.5M net loss, $56.3M cash and dosing the first two patients in its Phase 2b Alport syndrome study.

Expected impact

modest downside pressure as investors price the loss and cash usage

Evidence & confidence

The disclosed loss and reduced cash balance are material negative factors; however, the initiation of a Phase 2b trial provides a catalyst that may limit the sell‑off.

Market effects

Highlights ongoing investment in rare‑kidney disease biotech, may spur interest in similar small‑cap clinical‑stage firms.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

Despite the loss, the rare‑disease focus and early trial data could attract speculative buying on upside potential.

Key entities

  • Eloxx Pharmaceuticals, Inc.

    Clinical‑stage biotech developing exaluren for rare kidney diseases.

  • T.R. Srinivas, M.D.

    New SVP, Chief Medical Officer overseeing renal programs.

Every ELOX earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ELOXMedAI 8/10

Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash

Eloxx Pharmaceuticals reported a Q3 2026 net loss of $5.54M, or $0.49 per share, with $56.3M in cash. R&D expenses rose to $4.03M from a prior-year credit of $0.25M. The company dosed the first patients in its Phase 2b Alport syndrome study and received FDA clearance for an ADPKD study. It expects topline Alport study results in mid-2027.

$ELOXMedAI 8/10

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals (ELOX) reported Q3 2026 results, highlighting progress in clinical trials for exaluren in rare kidney diseases. The company dosed the first patients in a Phase 2b study for Alport syndrome and finalized a Phase 2 study for ADPKD. Eloxx had $56.3M in cash as of September 30, 2026, and expects it to last into 2028. The company also expanded its leadership team and reported a net loss of $5.5M for the quarter.

$ELOXMedAI 8/10

Eloxx receives FDA clearance for ADPKD drug trial in U.S.

Eloxx Pharmaceuticals (NASDAQ:ELOX) received FDA clearance to start a Phase 2 trial for exaluren, a treatment for autosomal dominant polycystic kidney disease (ADPKD). The EXPRESS trial will enroll 60 adults with nonsense mutations, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation and accelerated approval. Exaluren has orphan drug designation in the U.S. and Europe. ADPKD affects 160,000-200,000 people in the U.S.

$ELOXMedAI 8/10

Eloxx finalizes phase 2 trial design for rare kidney disease

Eloxx Pharmaceuticals (ELOX) finalized its Phase 2 trial design for exaluren in treating autosomal dominant polycystic kidney disease. The global trial will enroll 60 adults, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer. Exaluren has orphan drug designations in the U.S. and Europe.

$ELOXMedAI 8/10

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 study design for treating nonsense-mutation ADPKD with exaluren, expecting first patient dosing in 3Q 2027 and topline data in 1H 2029. The study will enroll 60 patients, with htTKV growth as the primary endpoint. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas, M.D., as Chief Medical Officer.